We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+5.18%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.58B
AUM Growth
+$79.4M
Cap. Flow
-$357M
Cap. Flow %
-3.72%
Top 10 Hldgs %
37.69%
Holding
157
New
16
Increased
39
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$158M
2
MOH icon
Molina Healthcare
MOH
+$98.2M
3
MRK icon
Merck
MRK
+$95.1M
4
ZBH icon
Zimmer Biomet
ZBH
+$88.5M
5
MDVN
MEDIVATION, INC.
MDVN
+$85.1M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$182M
2
CELG
Celgene Corp
CELG
+$142M
3
HCA icon
HCA Healthcare
HCA
+$129M
4
AGN.PRA
Allergan plc
AGN.PRA
+$87M
5
TSRO
TESARO, Inc.
TSRO
+$84.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Miscellaneous 5.91%
3 Financials 0.34%
4 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$65.3B
$541M 5.64%
23,129,200
+649,500
+3% +$14.1M
AMGN icon
2
Amgen
AMGN
$206B
$462M 4.82%
3,033,500
+157,500
+5% +$24.5M
ABBV icon
3
AbbVie
ABBV
$454B
$407M 4.25%
6,573,100
-822,600
-11% -$50.1M
BMY icon
4
Bristol-Myers Squibb
BMY
$131B
$372M 3.88%
5,055,600
-2,569,300
-34% -$182M
BIIB icon
5
Biogen
BIIB
$32.1B
$363M 3.79%
1,500,400
-25,900
-2% -$6.83M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$348M 3.63%
2,981,411
+1,110,811
+59% +$158M
HCA icon
7
HCA Healthcare
HCA
$92.4B
$316M 3.29%
4,098,300
-1,638,800
-29% -$129M
AGN
8
DELISTED
Allergan plc
AGN
$311M 3.24%
1,344,615
-228,100
-15% -$52.6M
GILD icon
9
Gilead Sciences
GILD
$182B
$256M 2.67%
3,072,900
+53,700
+2% +$4.77M
CELG
10
DELISTED
Celgene Corp
CELG
$237M 2.47%
2,404,677
-1,369,400
-36% -$142M
WCG
11
DELISTED
Wellcare Health Plans, Inc.
WCG
$206M 2.15%
1,918,500
+15,200
+0.8% +$1.49M
TMO icon
12
Thermo Fisher Scientific
TMO
$225B
$203M 2.12%
1,377,200
-57,800
-4% -$8.53M
ISRG icon
13
Intuitive Surgical
ISRG
$134B
$197M 2.06%
2,680,200
+189,000
+8% +$13.3M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$132B
$188M 1.97%
2,189,300
+319,900
+17% +$27.6M
INCY icon
15
Incyte
INCY
$24.8B
$186M 1.94%
2,324,678
-430,400
-16% -$33.4M
REGN icon
16
Regeneron Pharmaceuticals
REGN
$80.5B
$178M 1.86%
509,900
-23,100
-4% -$8.9M
UNH icon
17
UnitedHealth
UNH
$344B
$171M 1.78%
1,208,200
+396,200
+49% +$52.8M
IPXL
18
DELISTED
Impax Laboratories, Inc.
IPXL
$170M 1.77%
5,886,700
-889,400
-13% -$29M
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$160M 1.67%
1,120,000
– –
A icon
20
Agilent Technologies
A
$41.4B
$158M 1.65%
3,565,200
+70,200
+2% +$3.03M
PFE icon
21
Pfizer
PFE
$158B
$149M 1.56%
4,472,860
+128,272
+3% +$4.09M
TEVA icon
22
Teva Pharmaceuticals
TEVA
$45.1B
$139M 1.45%
2,759,800
+63,800
+2% +$3.4M
RLYP
23
DELISTED
RELYPSA INC COM
RLYP
$137M 1.43%
7,400,000
– –
IRWD icon
24
Ironwood Pharmaceuticals
IRWD
$689M
$130M 1.36%
11,879,106
-1,912,072
-14% -$18.7M
ESRX
25
DELISTED
Express Scripts Holding Company
ESRX
$129M 1.34%
1,698,600
-722,400
-30% -$53.1M
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2016 Portfolio in Review

As of Q2 2016, OrbiMed held 157 positions worth $9.58B, up 0.84% from $9.5B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed withdrew a net $357M in Q2 2016, closing 21 positions and reducing 32 holdings. Its most notable exit was Allergan plc, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in Molina Healthcare worth $91.7M.

  • OrbiMed's largest Q2 2016 buy was Molina Healthcare: 1,838,000 shares worth $91.7M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2016, an estimated $158M increase.
  • OrbiMed's biggest Q2 2016 reduction was Bristol-Myers Squibb, cutting an estimated $182M.
  • OrbiMed fully exited Allergan plc in Q2 2016, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 38% of its $9.58B portfolio in Q2 2016.
  • OrbiMed opened 16 new positions and closed 21 in Q2 2016.
  • OrbiMed's portfolio value rose 0.84% quarter-over-quarter to $9.58B.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.